stockrow
Friday 6 November 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024.
- Revenue
- −78.7%
- EPS
- +94.2%
- Free cash flow
- −257.7%
Quarter to June 2026, against a year earlier
0.80
0.04
−4.76%
Follow ISPC
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 4 | 4 | 8 | 11 | 10 | 10 | 9 | 2 | 0 | (11.1%) | 14 | — | — | +638.2% | |
| Gross margin, % | — | — | 46.24 | 50.50 | 56.19 | 52.86 | 54.27 | 51.45 | 42.93 | 1.25 | (108.26) | (45.0) pt | ||||||
| EBT | — | — | (5) | (5) | (5) | (9) | (10) | (11) | (12) | (10) | (11) | +9.7% | ||||||
| EBT margin, % | — | — | (124.56) | (113.63) | (56.84) | (80.48) | (98.50) | (111.80) | (134.51) | (543.68) | (2,449.02) | (419.1) pt | ||||||
| Net income | — | 0 | (5) | (5) | (5) | (9) | (10) | (11) | (12) | (10) | (11) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.67 | 3,582.00 | 6,820.08 | 2,062.09 | 937.14 | 878.60 | 521.97 | 16.76 | 0.33 | +58.4% | |||||
| Earnings | — | — | (0.81) | (4,039.80) | (3,976.14) | (1,672.00) | (928.00) | (984.00) | (703.20) | (91.20) | (52.65) | +96.4% | ||||||
| Cash flow | — | — | (0.41) | (2,233.25) | (240.33) | (1,975.63) | (524.12) | (513.95) | (464.25) | (36.84) | (5.02) | +90.1% | ||||||
| Capex | — | — | 0.00 | (2,435.25) | (1,837.33) | (383.94) | (555.58) | (419.88) | (38.47) | (8.69) | (1.22) | n/m | ||||||
| Free cash flow | — | — | (0.41) | (4,668.50) | (2,077.67) | (2,359.57) | (1,079.69) | (933.82) | (502.72) | (45.54) | (6.24) | +96.0% | ||||||
| Book value | — | — | (2.81) | (9,621.42) | (13,420.75) | 5,516.96 | 1,829.66 | 862.04 | 186.01 | 26.83 | 1.25 | n/m | ||||||
| Shares, m | — | — | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | (43.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | 0.73 | 0.73 | 0.73 | 3.03 | 1.20 | 0.48 | 0.32 | 1.04 | 2.39 | 1.0 | ||||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 1.13 | 0.62 | 0.49 | 0.91 | 0.65 | 0.64 | 0.5 | ||||||
| EV/Sales | — | — | 1.87 | 1.87 | 1.87 | 0.85 | (0.02) | 0.24 | 0.40 | (1.17) | (1.47) | 0.7 | ||||||
| EV/FCF | — | — | (28.11) | (28.11) | (28.11) | (0.74) | 0.01 | (0.18) | (0.34) | 0.30 | 0.06 | (10.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | (3) | 0 | (11) | (6) | (6) | (8) | (4) | (7) | +6.7% | |||||
| Capex | — | — | (1) | (3) | (2) | (2) | (6) | (5) | (1) | (1) | (2) | (0.4%) | ||||||
| Free cash flow | — | — | (3) | (6) | (2) | (13) | (12) | (11) | (9) | (5) | (9) | +10.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | (9) | (14) | (19) | 30 | 15 | 2 | (2) | 1 | (1) | n/m | |||||
| Net debt | — | — | 17 | 11 | (1) | (24) | (15) | (5) | (2) | (7) | (4) | n/m | ||||||
| Shareholders’ equity | — | — | (18) | (12) | (16) | 30 | 20 | 10 | 3 | 3 | 2 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (264.41) | (114.47) | (89.25) | (42.75) | (33.96) | (54.90) | (99.31) | (111.09) | (170.09) | +153.3 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (67.64) | (127.31) | (147.42) | (555.29) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 25.99 | 22.98 | 18.61 | (713.06) | (40.90) | (73.87) | (191.51) | (327.78) | (968.44) | (353.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 46 | 59 | 75 | 53 | 24 | 7 | — | (31.4%) | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.18 | 0.19 | 0.14 | 0.19 | 0.39 | 0.28 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
iSpecimen Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NDRA ENDRA Life Sciences Inc. | $7.5M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| XWEL XWELL, Inc. | $6.1M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $3.3M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| ADVB Advanced Biomed Inc. | $3.1M | 0.3× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | Compare |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| ISPC iSpecimen Inc. | $2.0M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | |
| PRPH ProPhase Labs, Inc. | $1.2M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 22.35% | (261.62%) | Compare |
| Median of peers | $3.3M | — | — | −7.08% | — | −4.32% | 22.35% | (155.23%) |
Pay and ownership Proxy statement filed 14 September 2026
Ownership
Directors and executive officers, together
less than 1%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement